Announcement PDF ASX Announcement 2 March 2020 ASX Market Announcements ASX Limited Level 4 Stock Exchange Centre 20 Bridge Street Sydney NSW 2000 Appendix 3Y – Dr Ross Murdoch Melbourne, Australia, 2 March 2020 – Avecho Biotechnology Limited (ASX: AVE), an Australian drug delivery company, advises that the attached 3Y reflects the non-vesting of options to Dr Ross Murdoch as the vesting conditions attached to the 15,000,000 2016 Options, as announced on 5 June 2017, had not been met. For enquiries, please contact Melanie Leydin Company Secretary +61 3 9692 7222 This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited. About Avecho Avecho Biotechnology Limited (ASX:AVE) develops and commercialises innovative Human Health, Animal Health and Personal Care products using its proprietary drug delivery system called TPM® (Targeted Penetration Matrix). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients. Avecho’s major projects include delivering TPM® enhanced patches, gels and injectable products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock. See more here - avecho.com.au Avecho Biotechnology Limited | ASX:AVE | ACN: 056 482 403 | ABN: 32 056 482 403 Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168 avecho.com.au Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity AVECHO BIOTECHNOLOGY LIMITED ABN 32 056 482 403 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Ross Murdoch Date of last notice 31 October 2017 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) N/A Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 26 February 2020 No. of securities held prior to change Direct 1,666,667 Fully Paid Ordinary Shares 15,000,000 2016 Options Class Fully Paid Ordinary Shares Number acquired Nil Number disposed 15,000,000 2016 Options not vested Value/Consideration Nil Note: If consideration is non-cash, provide details and estimated valuation + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice No. of securities held after change Direct 1,666,667 Fully Paid Ordinary Shares Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Vesting Conditions were not met (pursuant to the Appendix 3B announced on 5 June 2017). Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed No above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided? + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011